The Latest Plasma Fractionation Industry Statistics Explained
The global Plasma Fractionation market size was estimated at USD 22.2 billion in 2020.
The statistic indicates that the global Plasma Fractionation market was valued at USD 22.2 billion in the year 2020. Plasma fractionation is a process used to separate various components of blood plasma, such as proteins and antibodies, for therapeutic and commercial purposes. The market size figure reflects the total value of products and services related to plasma fractionation worldwide in that particular year. This estimate serves as a key indicator of the market’s economic significance and growth potential, providing valuable insights for stakeholders in the healthcare industry, including manufacturers, healthcare providers, and investors.
The Plasma Fractionation market is projected to reach USD 39.5 billion by 2026, at a CAGR of 7.6% during the forecast period.
This statistic indicates that the Plasma Fractionation market is expected to experience significant growth over the forecast period, reaching a value of USD 39.5 billion by 2026. The Compound Annual Growth Rate (CAGR) of 7.6% signifies the steady and consistent growth trajectory of the market. This projection suggests that the demand for plasma products and services, such as albumin, immunoglobulins, and clotting factors, is likely to increase over the coming years, driven by factors such as the rising prevalence of chronic and immune disorders, advancements in healthcare technology, and increasing awareness about plasma therapies. The positive outlook for the Plasma Fractionation market underscores the potential opportunities for stakeholders in this industry to capitalize on the growing demand and expand their market presence.
Europe accounted for the second largest share of the Plasma Fractionation market in 2020.
In 2020, Europe held the second largest portion of the Plasma Fractionation market, indicating the significance of this region in the industry. This statistic suggests that Europe is a major player in the Plasma Fractionation market, following closely behind the region with the largest market share. The substantial presence of Europe in the market illustrates the region’s contribution to the overall market dynamics and highlights it as a key market for Plasma Fractionation products and services. This data points towards Europe’s importance in the industry and emphasizes its influence on market trends and developments within the Plasma Fractionation sector.
Serum/Plasma Fractionation segment is expected to account for the largest share of the market.
This statistic indicates that within the market for serum/plasma fractionation, this specific segment is forecasted to have the highest proportion of total market sales or revenue compared to other segments. This suggests that serum/plasma fractionation products or services are likely to be in high demand or have significant market penetration relative to other segments within the industry. Factors driving this prediction could include the increasing prevalence of diseases that require serum/plasma-based treatments, advancements in technology leading to more effective fractionation processes, or shifting regulatory guidelines favoring these products. As a result, companies operating in the serum/plasma fractionation segment may have a competitive advantage and opportunities for growth within the market.
Among several applications, neurology segment dominated the plasma fractionation market in 2019.
In 2019, the dominance of the neurology segment in the plasma fractionation market suggests that this particular field within medicine accounted for the highest share of applications utilizing plasma-derived products. Plasma fractionation involves separating and purifying plasma components to produce therapeutic products such as immunoglobulins and clotting factors, which are crucial for treating various neurological disorders and conditions. The prevalence of neurological diseases like multiple sclerosis, Alzheimer’s, and Parkinson’s may have driven the demand for plasma-derived treatments within this segment, leading to its dominance in the market. This statistic highlights the significant role that plasma fractionation plays in catering to the specific needs of patients with neurological illnesses and underscores the importance of ongoing research and development in this area to further improve treatment options.
Immunoglobulin dominated the Plasma Fractionation market in terms of product type in 2020.
The statement means that in 2020, immunoglobulin products held the largest share of the Plasma Fractionation market in terms of product types. This indicates that immunoglobulins, which are a class of proteins that play a key role in the body’s immune response, were the most commonly produced and utilized products within the Plasma Fractionation industry during that year. The dominance of immunoglobulins suggests a high demand for these products, likely due to their crucial therapeutic applications in treating various immune-related disorders and diseases. This statistic highlights the significant presence and importance of immunoglobulins within the Plasma Fractionation market landscape in 2020.
The plasma protease inhibitors market is the fastest-growing product market segment.
The statistic “The plasma protease inhibitors market is the fastest-growing product market segment” indicates that among all product market segments, the plasma protease inhibitors market is experiencing the highest rate of growth in terms of sales, revenue, or market share. This suggests a strong demand for plasma protease inhibitors compared to other products in the market, leading to increased sales and market expansion. Such rapid growth may be driven by factors such as increasing awareness of the benefits of plasma protease inhibitors, advancements in medical research and technology, favorable regulatory environments, or shifting consumer preferences towards these products. Monitoring and investing in this segment could present lucrative opportunities for businesses operating in the healthcare or pharmaceutical industry.
China represented the largest country-wise market in the Asia Pacific region in 2020.
The statistic indicates that in 2020, China had the highest market share among all countries in the Asia Pacific region. This means that China had the largest volume of economic activity, trade, or consumption compared to any other country in the region during that year. This could be due to various factors such as population size, strong economic growth, industrial output, or consumer demand. The prominence of China as the largest market in the Asia Pacific region signifies the significant influence and importance of the country in the regional economy and highlights the potential opportunities and challenges for businesses operating in this market.
The coagulation factor concentrates application segment is expected to grow at a high CAGR in the forecast period.
The statistic indicates that the application segment of coagulation factor concentrates is projected to experience significant growth over the forecast period, as measured by a high Compound Annual Growth Rate (CAGR). This suggests a strong demand for coagulation factor concentrates in various medical treatments and procedures, such as hemophilia and other bleeding disorders. The expected high CAGR reflects increasing recognition and adoption of these concentrates in clinical settings, driven by a growing patient population, advancements in treatment options, and a greater awareness of the benefits they offer. Overall, the forecasted growth in this segment signifies a promising outlook for the market of coagulation factor concentrates in the coming years.
The recent outbreak of Covid-19 has resulted in increased use of immunoglobulins and is contributing to the growth of the industry.
The statistic highlights the impact of the recent Covid-19 outbreak on the use of immunoglobulins and the subsequent growth of the industry. Given the infectious nature of the virus and its ability to affect individuals with varying degrees of severity, the need for treatments such as immunoglobulins, which can help boost the immune response, has increased significantly. As a result, the demand for immunoglobulins has risen, leading to growth within the industry. This trend underscores the critical role that immunoglobulins play in addressing the healthcare needs of individuals during the pandemic and reflects how the outbreak has shaped patterns of consumption and production in the field of immunology.
In 2019, hemophilia accounted for a substantial portion of the plasma fractionation market on behalf of transfusion medicine.
The statistic indicates that in 2019, hemophilia was a significant contributor to the plasma fractionation market within the field of transfusion medicine. This implies that a considerable portion of the market demand for plasma-derived products was driven by the treatment of hemophilia patients. Hemophilia is a genetic bleeding disorder that requires regular infusions of clotting factors derived from plasma to manage and prevent bleeding episodes. As hemophilia is a chronic condition that necessitates lifelong treatment, it is not surprising that it has a notable presence in the plasma fractionation market, where plasma is processed to extract essential clotting proteins for therapeutic use in patients with bleeding disorders like hemophilia.
Alzheimer’s is predicted to serve as the most lucrative segment in the years ahead due its high presence and the increasing geriatric population.
The statistic suggests that the market segment focusing on Alzheimer’s disease is anticipated to become increasingly profitable in the future. This prediction is based on the high prevalence of Alzheimer’s disease among the global population and the expected growth of the geriatric population. As the number of elderly individuals rises, the demand for treatments, medications, and healthcare services related to Alzheimer’s is likely to increase, leading to a potentially lucrative market opportunity for pharmaceutical companies, healthcare providers, and other organizations operating within this sector. This statistic highlights the potential for significant economic impact and business growth within the Alzheimer’s disease market in the coming years.
Hospitals dominated the end use segment in 2020, capturing over 48.5% of the market share.
The statistic indicates that hospitals were the primary consumers within a particular market segment in 2020, accounting for more than 48.5% of the total market share. This dominance suggests that hospitals significantly influenced the demand and consumption patterns within the industry during that year. Since hospitals are critical players in the healthcare system, their considerable market share indicates a strong presence and reliance on the products or services offered within this market segment. This information highlights the importance of catering to the needs and preferences of hospitals as key customers to maintain and expand market reach within this industry.
As of 2020, a few key players held a dominant share in the global plasma fractionation industry, including CSL Ltd., Grifols, S.A., and Shire Plc.
This statistic indicates that as of 2020, a small number of major companies, including CSL Ltd., Grifols, S.A., and Shire Plc, held a significant portion of the market share in the global plasma fractionation industry. These key players likely had established themselves as leaders in the industry due to various factors such as brand reputation, technological advancements, scale of operations, and regulatory compliance. Their dominance suggests that they have a strong competitive position and influence over market trends, pricing, and potentially innovation within the plasma fractionation sector. This concentration of market power among a few major players may have implications for competition, pricing, and the overall dynamics of the global plasma fractionation market.
The rising number of industry-academia collaborations for plasma research is driving the plasma fractionation market.
The statistic indicates that there is a growing trend of collaboration between industry and academia in the field of plasma research. This mutual partnership likely involves sharing resources, expertise, and knowledge to conduct research and develop technologies related to plasma fractionation. As a result of these collaborations, advancements are being made in the field of plasma fractionation, which is the process of separating plasma into its components for various medical and pharmaceutical applications. The combined effort of industry and academia is likely driving innovation and growth in the plasma fractionation market by facilitating the development of new products, therapies, and technologies.
One of the latest trends in the market is the growing importance of contract manufacturing organizations.
The statistic “One of the latest trends in the market is the growing importance of contract manufacturing organizations” suggests that a notable shift is occurring where businesses are increasingly relying on external companies for their manufacturing needs rather than producing goods in-house. This trend may indicate that companies are seeking more cost-effective and flexible solutions by outsourcing their manufacturing processes to specialized organizations that can offer expertise, efficiency, and scalability. The rise of contract manufacturing organizations reflects a strategic move by businesses to stay competitive in the market, adapt to changing demands, and optimize their operational processes. This trend highlights the evolving dynamics of the manufacturing industry and the importance of strategic partnerships in today’s business landscape.
References
0. – https://www.www.grandviewresearch.com
1. – https://www.www.marketresearchfuture.com
2. – https://www.www.fortunebusinessinsights.com
3. – https://www.www.zionmarketresearch.com
4. – https://www.www.reportsanddata.com
5. – https://www.www.marketsandmarkets.com
6. – https://www.www.bccresearch.com
